Study ID Type of CHD and syndrome Members (I/C) Age Gender (M/F) Interventions group Control group Product Outcome evaluation
Du and Chen 2009 [21 ] UA 56/56
62/50 C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular heparin 5–7 days, antihypertensive drugs and medicine used to treat 2 diabetes) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, Z19990022, containing PNS 60 mg/capsule) Angina pectoris (extension, frequency, duration), dosage of nitroglycerin, Ads.
Ge and Zhao 2010 [22 ] UA 48/48 I: 56; C: 54 (in average) I: 22/26 V: 25/23 C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular heparin 5–7 days, antihypertensive drugs and medicine used to treat 2 diabetes) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming China, Z19990022, containing PNS 60 mg/capsule) Angina pectoris relievement, ECG, Ads.
Han and Chen 2008 [23 ] PCI patients 30/30 I: (
); C: (
) I: 23/7; C: 21/9 C + Xuesaitong softy capsule, 2 capsules, BID in the first 2 weeks, then 1 capsule, TID, 12 weeksConventional therapy (anticoagulant agent, antiplatelet agent, medicine for modifying blood lipid, antihypertensive drug and medicine used to treat 2 diabetes) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, Z19990022, containing PNS 60 mg/capsule) Angina pectoris, rehospitalization
Ji and Zhang 2003 [24 ] UA 30/90 I1: (
); I2: (
); I3: (
); C: (
) I1: 20/10; I2: 18/12; I3: 21/9; C: 17/13 I1: C + coarse power 1 g, TID; I2: C + semi-micron power 1 g, TID I3: C + micron power 1 g, TID Isosorbide Mononitrate 20 mg BID; Aspirin 75 mg, QD; Metoprolol 25 mg BID; DTZ 30 mg, TID or QID; Plendil 5 mg QD or BID or Acertil 4 mg, QD for hypertension; Nitroglycerol 0.5 mg subligual administration or nitroglycerol injection 10 mg, iv. Panax notoginseng coarse power: WF-2000 pulverizer; Panax notoginseng micron power: BFM-6 pulverizer; Panax notoginseng semi-micron power: BFM-6 pulverizer and starch. Efficacy of Angina pectoris, ECG, symptoms, Ads
Liu et al. 2008 [19 ] UA and BSS 30/30 I: (
); C: (
) Unclear C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (no detail) Xuesaitong softy capsule (Yunnan weihe Pharmaceutical company, containing PNS 60 mg/capsule) Syndrome, pulse, heart rate, heart rhythm, blood pressure, angina pectoris, ECG Meng 2003 [25 ] UA and SA 60/20 I: (61–78); C: (61–78) I: 44/16 C: 16/4 PNS pill, 2 tablets, sublingual when angina pectoris attacked Isosorbide dinitrate when angina pectoris attacked (5 mg/tables) PNS pill, 2 tablet**, Sublingual Duration of angina pectoris relievement, blood pressure, heart rate, and ECG after 2 hours of prescription.
Song et al. 2005 [26 ] Unclear 50/50 I: (36–77), (
); C: (38–74), (
) in average I: 31/19 C: 33/17 C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular heparin 5–7 days, antihypertensive drugs and medicine used to treat diabetes) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China) Efficacy of angina pectoris, ECG, dosage of nitroglycerin Wan 2011 [27 ] UA 26/26 I: 65.7 in average; C: No report I: 15/11 C: 13/13 C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent and et al.) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China) Efficacy of angina pectoris, ECG
Wang et al. 2009 [28 ] UA 100/100 36–75 Unclear T1:C1 + Xuesaitong softy capsule, 2 capsules, BID, 30 days;T2:C2 + trimetazidine + Xuesaitong softy capsule, 2 capsules, BID, 30 days;C1: conventional therapy (ant platelet, Nitrates, CCB, β blocker agent, statin, trimetazidine); C2: Conventional therapy (ant platelet, Nitrates, CCB, β blocker agent, astatine) Xuesaitong softy capsule Efficacy of angina pectoris and cardiovascular events in 30 d followup. Wei 2010 [29 ] Unclear 90/90
113/67 C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (Nitrate, β blocker agent, CCB, low molecular heparin) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China) Angina pectoris, Ads, ECG Yan 2005 [30 ] Unclear 24/24 I: (48–67), 60 in average; C: (47–69), 62 in average I: 13/11 C: 14/10 Isosorbide mononitrat 5 mg TID + Panax notoginseng power 6 g BID, 7 days Isosorbide Mononitrate, 10 mg, TID Panax notoginseng power 6 g BIDEfficacy of angina pectoris, ECG, ADs Yu 2010 [31 ] UA 50/50 I: (
); C: (
) I: 29/21 C: 28/22 C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB and et al.) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China) Efficacy of angina pectoris, ECG, ADs, cardiovascular events
Zhou and Bai 2009 [32 ] Unclear 43/43
I: 32/11 C: 34/9 C + Xuesaitong softy capsule, 2 capsules, TID, 4 weeksConventional therapy (nitrate, Metoprolol, aspirin, Nitroglycerin if necessary) Xuesaitong softy capsuleΔ (Luotai, Kunming Pharmaceutical incorporated corporation) Efficacy of angina pectoris, ECG
Kuang et al. 2011 [33 ] UA 90/90 I: (
); C: (
) I: 47/43 C: 46/44 C + Xuesaitong softy capsule, 2 capsules, BID, 4 weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, low molecular dextran, and others) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, containing PNS 60 mg/capsule) Efficacy of angina pectoris, ECG, ADs Bao 2011 [34 ] SA, BSS 63/64 I: (52.3 in average); C: (51.6 in average) I: 35/28 C: 37/27 C + Sanqi guanxinning tablets (Z53020028), 2–4 tables, TID, 6 weeksConventional therapy (nitroglycerin, β blocker agent, and others) Sanqi guanxinning tabletsΔΔ (Z53020028) Efficacy of angina pectoris
Zhao and Li 2012 [35 ] SA 60/58 I: (
, 42–70); C: (
, 41–68) I: 38/22 C: 40/18 C + Xuesaitong softy capsule, 2 capsules, TID, 4 weeksConventional therapy (aspirin, J20080078, 100 mg) Qd, isosorbide mononitrate (H20030418, 60 mg Qd), β blocker (H32025391) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, Z19990022) Efficacy of ECG Yang 2012 [36 ] Unclear 14/14 (
), 51–78 19/9 C + Xuesaitong softy capsule, 2 capsules BID in the first two weeks, 1 capsule BID in the later weeksConventional therapy (aspirin, β blocker agent, nitroglycerin, CCB, and others) Xuesaitong softy capsule* (Shenghuo Pharmaceutical Holdings Yunnan kunming, China, containing PNS 60 mg/capsule) Frequency of angina pectoris, dosage of nitroglycerin, frequency of premature ventricular contraction